[1]
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52.
[2]
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 2017; 38: 2459-72.
[3]
McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res 2016; 118: 564-78.
[4]
Wiegman A, Gidding SS, Watts GF, et al. European atherosclerosis society consensus panel. Familial hypercholesterolaemia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36: 2425-37.
[5]
Nikpay M, Goel A, Won HH, et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015; 47: 1121-30.
[6]
Linsel-Nitschke P, Gotz A, Erdmann J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease: A mendelian randomisation study. PLoS One 2008; 3: e2986.
[7]
Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-39.
[8]
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
[9]
Peterlin A, Petrovič D, Peterlin B. Screening for rare genetic variants associated with atherosclerosis: Opportunity for personalized medicine. Curr Vasc Pharmacol 2019; 17(1): 25-8.
[10]
Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: Facts and fallacies. Nat Rev Endocrinol 2016; 12: 616-22.
[11]
Nathan DM, Cleary PA, Backlund JY, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
[12]
Choby B. Diabetes update: Prevention and management of diabetes complications. FP Essent 2017; 456: 36-40.
[13]
Lunder M, Janić M, Šabovič M. Prevention of vascular complications in diabetes mellitus patients: Focus on the arterial wall. Curr Vasc Pharmacol 2019; 17(1): 6-15.
[14]
Versari D, Daghini E, Virdis A, Ghiadoni L, Tadei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32(Suppl. 2): 314-21.
[15]
Janic M, Lunder M, Sabovic M. Arterial stiffness and cardiovascular therapy. BioMed Res Int 2015; 2015: 235709.
[16]
Vinkhuyzen AA, Wray NR, Yang J, Goddard ME, Visscher PM. Estimation and partition of heritability in human populations using whole- genome analysis methods. Annu Rev Genet 2013; 47: 75-95.
[17]
Ramuš-Mankoč S, Petrovič D. Genetic variations and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus. Curr Vasc Pharmacol 2019; 17(1): 16-24.
[18]
Cole CB, Nikpay M, McPherson R. Gene-environment interaction in dyslipidemia. Curr Opin Lipidol 2015; 26: 133-8.
[19]
Sousa AG, Selvatici L, Krieger JE, Pereira AC. Association between genetics of diabetes, coronary artery disease, and macrovascular complications: Exploring a common ground hypothesis. Rev Diabet Stud 2011; 8: 230-44.
[20]
Machal J, Hlinomaz O. Efficacy of P2Y12 receptor blockers after myocardial infarction and genetic variability of their metabolic pathways. Curr Vasc Pharmacol 2019; 17(1): 35-40.
[21]
Boncelj Svetek M, Erzen B, Kanc K, Sabovic M. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. J Diabetes Complications 2017; 31: 544-50.
[22]
Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation 2016; 133: 1073-80.
[23]
Wang S, Head BP. Caveolin-1 in stroke neuropathology and neuroprotection: A novel molecular therapeutic target for ischemic-related injury. Curr Vasc Pharmacol 2019; 17(1): 41-50.
[24]
Fabjan A, Bajrović FF. Novel direct anticoagulants and atherosclerosis. Curr Vasc Pharmacol 2019; 17(1): 29-34.
